HCA Corporation
HCA
$431.92
-3.11%
HCA Healthcare, Inc. is a leading provider of healthcare services, operating the largest collection of acute-care hospitals in the United States, with a portfolio of 190 hospitals and over 2,500 outpatient facilities. The company is a dominant market leader in the Medical Care Facilities industry, distinguished by its massive scale, geographic diversification across 19 states, and a vertically integrated model that provides significant operational leverage. The current investor narrative centers on its demonstrated operational resilience and strong financial performance amidst a challenging labor and regulatory environment, with recent news highlighting its potential as a long-term winner benefiting from demographic trends like an aging American population.…
HCA
HCA Corporation
$431.92
Related headlines
Investment Opinion: Should I buy HCA Today?
Rating & Thesis: HCA is a Hold at current levels. The core thesis is that the stock presents a compelling fundamental value proposition (PEG 0.56, forward PE 12.98x) but is caught in a severe technical downdraft and carries significant balance sheet risk, making immediate entry premature despite analyst confidence.
Supporting Evidence: The valuation is reasonable, with a forward PE of 12.98x and a PEG ratio of 0.56 suggesting undervaluation relative to growth. Revenue growth remains healthy at 6.72% YoY, and profitability is strong with a 15.8% operating margin. However, these positives are counterbalanced by the stock's severe technical weakness (trading at 22.3% of its 52-week range) and leveraged balance sheet (D/E of -8.33). The lack of a clear analyst price target consensus adds uncertainty to the near-term upside potential.
Risks & Conditions: The two biggest risks are the continuation of the technical downtrend and a deterioration in the balance sheet metrics. This Hold rating would upgrade to a Buy if the stock stabilizes above the key March low of $467.83, signaling the technical breakdown has been arrested, or if the company demonstrates material debt reduction. It would downgrade to a Sell if the price breaches the $470 support level on high volume and moves decisively toward the 52-week low. Relative to its history and peers, the stock appears fairly valued to slightly undervalued on earnings growth, but the technical and balance sheet overhangs justify a cautious stance.
Sign up to view all
HCA 12-Month Price Forecast
The AI assessment is Neutral with Medium confidence. HCA presents a complex picture where attractive fundamentals are currently being discounted due to technical selling and balance sheet concerns. The forward PE of 12.98x and strong cash flow generation provide a valuation floor, but the high beta and negative equity signal elevated risk. The most likely path is a period of volatile consolidation (base case, 55% probability) as the market digests these conflicting signals. The stance would upgrade to Bullish on a confirmed technical reversal above $474 with volume, indicating the sell-off has exhausted. It would downgrade to Bearish on a break below $467 with a high probability of testing the $321 low, which would signal a fundamental breakdown in investor thesis.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HCA Corporation's 12-month outlook, with a consensus price target around $561.50 and implied upside of +30.0% versus the current price.
Average Target
$561.50
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$346 - $562
Analyst target range
Analyst coverage for HCA is limited, with only 5 analysts providing estimates, which suggests it may have less institutional scrutiny than larger mega-cap peers, potentially leading to higher volatility. The average revenue estimate for the next period is $100.42 billion, with a range from $98.60 billion to $102.86 billion, indicating a relatively tight consensus and moderate growth expectations; however, explicit price targets and a consensus recommendation are not available in the provided data, limiting sentiment analysis. The recent institutional ratings show a pattern of reiterated bullish stances from firms like TD Cowen, Mizuho, and UBS in early 2026, with no downgrades, signaling underlying confidence among covering analysts despite the stock's recent technical weakness.
Bulls vs Bears: HCA Investment Factors
The investment debate for HCA is a classic clash between strong fundamentals and deteriorating technicals. The bull case is anchored in robust profitability, compelling valuation (PEG of 0.56), and resilient revenue growth of 6.72% YoY. The bear case is driven by a severe technical breakdown, high volatility (beta 1.37), and concerning balance sheet metrics like a negative D/E ratio. Currently, the bearish technical momentum appears to have the upper hand, as the stock has broken key support and is severely underperforming the market. The single most important tension is whether the market's negative technical reaction is a temporary overreaction to sector-wide concerns or a correct repricing of fundamental risks, particularly around financial leverage and liquidity. The resolution of this tension will determine if the stock reverts to its fundamental value or continues its downtrend.
Bullish
- Strong Profitability & Cash Flow: HCA generates robust margins with a Q4 gross margin of 41.9% and operating margin of 15.8%, translating to $1.88 billion in net income. The company's trailing twelve-month free cash flow of $7.69 billion provides significant financial flexibility for shareholder returns and reinvestment.
- Undervalued PEG Ratio: With a PEG ratio of 0.56, HCA's valuation appears compelling relative to its earnings growth rate. This suggests the stock is not overpriced for its growth, especially when compared to its own historical trailing PE of 15.88x, which is below its recent high of 20.79x.
- Resilient Revenue Growth: Q4 2025 revenue grew 6.72% year-over-year to $19.51 billion, demonstrating sustained demand. Sequential growth from Q3's $19.16 billion further indicates operational momentum despite industry headwinds.
- Analyst Confidence Amid Weakness: Despite the recent sharp price decline, institutional analysts from TD Cowen, Mizuho, and UBS reiterated bullish stances in early 2026. This underlying confidence suggests the sell-off may be overdone relative to the fundamental outlook.
Bearish
- Severe Technical Breakdown: The stock is in a pronounced downtrend, trading at $432.46, which is only 22.3% of its 52-week range and represents an 8.8% single-day drop. It has underperformed the S&P 500 by 19.35% over the past month, signaling a clear loss of momentum and investor confidence.
- Elevated Volatility & Beta: HCA's beta of 1.37 indicates it is 37% more volatile than the broader market. This high volatility, combined with a recent max drawdown of -20.67%, makes the stock riskier, especially during market downturns or sector-specific sell-offs.
- Weak Balance Sheet Structure: The company's debt-to-equity ratio is a concerning -8.33, and its current ratio is 0.83. This negative equity and sub-1.0 liquidity ratio point to a leveraged financial structure and potential short-term liquidity constraints that warrant close monitoring.
- Negative Relative Strength: HCA has shown significant underperformance across all measured periods, with a -12.76% relative strength year-to-date and -11.75% over three months. This persistent weakness suggests the stock is being actively sold by institutional money.
HCA Technical Analysis
The stock is in a pronounced downtrend from recent highs, with the current price of $432.46 representing a significant 8.8% single-day drop and positioning it at only 22.3% of its 52-week range ($321.39 to $556.52), indicating it is trading much closer to its annual low than its high. Despite a positive 1-year return of 26.67%, the recent momentum has sharply reversed, with the stock down 10.65% over the past month and 8.16% over the past three months, signaling a clear deceleration and potential trend breakdown from its earlier strength. Key technical support is firmly established at the 52-week low of $321.39, while immediate resistance lies at the recent breakdown level near $474; a sustained break below the March low of $467.83 would signal further weakness, and the stock's elevated beta of 1.37 confirms it is significantly more volatile than the broader market, which is critical for risk assessment given the current sell-off.
Beta
1.37
1.37x market volatility
Max Drawdown
-20.8%
Largest decline past year
52-Week Range
$330-$557
Price range past year
Annual Return
+30.1%
Cumulative gain past year
| Period | HCA Return | S&P 500 |
|---|---|---|
| 1m | -8.5% | +12.2% |
| 3m | -12.1% | +2.3% |
| 6m | -7.5% | +4.7% |
| 1y | +30.1% | +29.2% |
| ytd | -8.2% | +4.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HCA Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $19.51 billion representing a 6.72% year-over-year increase, and a sequential uptick from Q3's $19.16 billion, indicating sustained demand across its hospital network. Profitability is strong, with the company generating a net income of $1.88 billion in Q4, a gross margin of 41.9%, and an operating margin of 15.8%, reflecting efficient cost management and pricing power in its core markets. The balance sheet and cash flow generation are solid, with trailing twelve-month free cash flow of $7.69 billion providing ample internal funding for growth and shareholder returns, though a negative debt-to-equity ratio of -8.33 and a current ratio of 0.83 warrant monitoring of financial structure and short-term liquidity.
Quarterly Revenue
$19.5B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.41%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HCA Overvalued?
Given the company's substantial net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. HCA trades at a trailing PE of 15.88x and a forward PE of 12.98x; the lower forward multiple suggests the market expects earnings growth, though the modest gap implies expectations are tempered. Compared to sector averages, HCA's trailing PE of 15.88x appears reasonable for a healthcare services leader, especially when considering its net margin of 8.97% and a PEG ratio of 0.56, which indicates the stock may be undervalued relative to its growth prospects. Historically, the current trailing PE of 15.88x is below the stock's own 5-year high observed in recent quarters (e.g., 20.79x in Q3 2024), suggesting the valuation has compressed and may not be pricing in overly optimistic expectations, potentially offering a margin of safety.
PE
15.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HCA's financial structure presents clear risks, primarily its negative debt-to-equity ratio of -8.33, which indicates significant leverage and a technically insolvent balance sheet on a book-value basis. While strong cash flow ($7.69B TTM FCF) mitigates near-term solvency concerns, the current ratio of 0.83 suggests potential strain in meeting short-term obligations without refinancing. Furthermore, the company's profitability, while strong, is sensitive to labor costs and reimbursement rates from government payors, which could pressure its 8.97% net margin if the operating environment deteriorates.
Market & Competitive Risks: The stock's high beta of 1.37 makes it highly sensitive to broader market moves, and its recent 8.8% single-day drop demonstrates this volatility. Trading at a trailing PE of 15.88x, which is below its own 5-year high of 20.79x, suggests valuation compression has already occurred, but further multiple contraction is possible if growth expectations falter. Competitive and regulatory headwinds are persistent in healthcare, and any adverse policy changes could impact volumes or pricing. The recent news highlighting 'near-term policy headwinds' underscores this ongoing external risk.
Worst-Case Scenario: The worst-case scenario involves a combination of a broader market correction (exacerbated by HCA's high beta), a miss on revenue or earnings estimates triggering analyst downgrades, and a realization of balance sheet stress leading to credit rating concerns. This could catalyze a rapid sell-off towards the 52-week low of $321.39. From the current price of $432.46, this represents a realistic downside of approximately -25.7%. A re-test of this low is plausible if the current technical breakdown accelerates and fundamental confidence erodes further.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The highly leveraged balance sheet, evidenced by a negative debt-to-equity ratio of -8.33 and a current ratio of 0.83, poses refinancing and liquidity risks. 2) Market/Volatility Risk: With a beta of 1.37, HCA is 37% more volatile than the market, amplifying losses during downturns, as seen in its recent -20.67% max drawdown. 3) Operational Risk: Exposure to government reimbursement rates and labor cost inflation could pressure its strong 15.8% operating margin. 4) Technical Risk: The stock is in a confirmed downtrend, trading near 52-week lows, which can become a self-fulfilling prophecy as momentum investors exit.
The 12-month outlook presents three scenarios. The Base Case (55% probability) forecasts range-bound trading between $470 and $510, assuming fundamentals hold but technical and balance sheet overhangs persist. The Bull Case (25% probability) sees a rally to $540-$556 if fundamentals overpower the sell-off. The Bear Case (20% probability) warns of a decline toward the 52-week low of $321 if the breakdown accelerates. The most likely outcome is the Base Case, hinging on the assumption that HCA's strong cash flows and market position prevent a deeper fundamental de-rating despite near-term volatility.
Based on traditional metrics, HCA appears fairly valued to slightly undervalued. Its forward PE of 12.98x is reasonable for a healthcare leader, and the PEG ratio of 0.56 is well below 1.0, which typically signals the stock is cheap relative to its growth rate. Compared to its own history, the trailing PE of 15.88x is below its recent high of 20.79x, indicating valuation compression has already occurred. The market is pricing in moderate growth expectations but is also applying a discount for the company's financial leverage and sector-specific headwinds.
HCA is a Hold, not a clear Buy at the current moment. While its fundamentals are strong with a 6.72% revenue growth rate, a PEG ratio of 0.56 suggesting undervaluation, and robust free cash flow, the stock is in a severe technical downtrend and carries balance sheet risks (D/E -8.33). It could be a good buy for patient, value-focused investors willing to average in on weakness, but only after the technical selling shows signs of exhaustion, such as a stabilization above the $467 support level. The high beta of 1.37 means it is suitable only for those with higher risk tolerance.
HCA is better suited for a long-term investment horizon of 3+ years. Its high beta (1.37) and current technical weakness make it a poor candidate for short-term trading, as volatility can lead to significant drawdowns. However, its long-term demographic tailwinds, scale, and cash-generative business model support a multi-year holding period where investors can benefit from earnings growth and potential multiple expansion once current headwinds subside. The minimal dividend yield of 0.63% indicates it is not an income stock, reinforcing its role as a long-term capital appreciation holding within a diversified portfolio.